2020-12-15 by Proactive Australia
MGC Pharmaceuticals Ltd s (ASX:MXC)(OTCMKTS:MGCLF)(FRA:H5O) Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment ArtemiC, based on Swiss PharmaCan AG MyCell Enhanced
TM delivery system technology, on those diagnosed with COVID-19, has met all the Phase II primary and secondary endpoints and demonstrated to improve the clinical recovery of the patients.
The European-based biopharma company specialising in the production and development of phytocannabinoid-derived medicines is now in a strong position to respond to a significant potential increase in the demand for ArtemiC in the immediate future as a supplement, and in the future as part of a Phase III study.